BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 94,100 shares, a growth of 6.2% from the September 30th total of 88,600 shares. Based on an average trading volume of 60,800 shares, the short-interest ratio is currently 1.5 days.
BioStem Technologies Trading Up 6.1 %
Shares of OTCMKTS:BSEM traded up 1.03 during mid-day trading on Wednesday, reaching 18.00. The stock had a trading volume of 81,000 shares, compared to its average volume of 29,678. The company has a market cap of $293.18 million, a P/E ratio of 43.50 and a beta of 0.05. BioStem Technologies has a 1 year low of 2.26 and a 1 year high of 18.75. The business's 50 day moving average price is 11.11 and its 200 day moving average price is 9.77.
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported 0.30 EPS for the quarter, topping analysts' consensus estimates of 0.12 by 0.18. The firm had revenue of 74.49 million during the quarter, compared to analysts' expectations of 43.99 million. Analysts predict that BioStem Technologies will post 1.13 earnings per share for the current fiscal year.
BioStem Technologies Company Profile
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Further Reading
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
